Attendance at European Congress of Radiology

RNS Number : 0284G

Feedback PLC

27 February 2015

 

27 February 2015

Feedback plc

("Feedback", the "Company" or the "Group")

Attendance at European Congress of Radiology

Feedback plc will be attending the European Congress of Radiology ("ECR") - the scientific assembly and annual meeting of the European Society of Radiology from 4th March to 8th March 2015 at the Austria Center in Vienna, Austria. Dr. Balaji Ganeshan, Chief scientist & New Business Officer, TexRAD Limited & Cambridge Computed Imaging Limited ("CCI") and other collaborators will be presenting a number of TexRAD related papers particularly in breast (novel quantitative radiomic analysis to identify high-risk breast cancer phenotype on PET-CT), colorectal (pre-operative CT texture analysis predicts outcome in patients with colorectal liver metastases post liver resection and MR texture analysis was a better marker of response to Neoadjuvant Chemotherapy in rectal cancer patients on 3-T MR than diffusion and perfusion parameters) and lung (multi-parametric PET-CT correlates with hypoxia, angiogenesis and ALK expression) cancers at ECR.

For further information contact:

Feedback plc	Tel: [phone]
Simon Barrell/Trevor Brown/Tom Charlton
Sanlam Securities UK (Nominated adviser)
Simon Clements / Virginia Bull	Tel: [phone]

Notes to editors:

TexRAD (is a novel sophisticated imaging risk stratification research tool that analyses the textures in existing radiological scans.  This research software application analyses textures, detecting and measuring tumour heterogeneity (complexity) from these images, revealing more information from medical images than it is currently possible to see with the naked eye. Research to date has shown that TexRAD could potentially assist the clinician (as an 'Imaging-Biomarker') in confident decision-making: assessing the prognosis, disease-severity (e.g. risk of metastases) and response evaluation of patients with cancer.  Currently TexRAD research has shown great potential in many different oncological sites, including, colorectal, breast, lung, prostate, oesophageal, head & neck, lymphoma, liver and renal cancers and could potentially be employed as a heterogeneity assessing tool in the era of 'Precision and Personalized Medicine'.TexRAD is manufactured under licence by the ISO 13485 certified company Cambridge Computed Imaging Ltd, a subsidiary of Feedback plc. More information is available on www.fbk.com and www.texrad.com.

 

END

 

 

NRABIGDDBBDBGUL